1. Introduction
Mitral valve replacement (MVR) is an established treatment for clinically significant mitral valve dysfunction when valve reconstruction cannot provide reliable and durable function. Unlike mitral valve repair, replacement substitutes a prosthetic orifice for the native valve and introduces lifelong considerations related to thrombosis, structural durability, prosthesis size, and ventricular geometry. The central decision is therefore not simply whether the valve can be replaced, but whether replacement provides a better long-term result than a feasible repair. Contemporary guidelines favor durable repair for primary degenerative mitral regurgitation when an experienced team anticipates a satisfactory result. [1,2]
The accompanying illustration contrasts normal segmental anatomy, a markedly prolapsing or restricted diseased valve, and a mechanical bileaflet prosthesis. These are representative morphologies, not categorical indications: even extensive degenerative prolapse may be repairable in expert centers, while an apparently localized lesion may prove unsuitable for durable reconstruction because of tissue quality, subvalvular pathology, or prior failed repair.
2. Indications: When Replacement Is Preferable
2.1. Severe mitral regurgitation
The decision to intervene for severe primary mitral regurgitation depends on symptoms, left ventricular dimensions and function, atrial fibrillation, pulmonary hypertension, and anticipated repair durability. Once surgery is indicated, repair remains the preferred operation when durable competence is likely. Replacement becomes appropriate when extensive leaflet destruction, marked restriction, severe calcification, insufficient mobile leaflet tissue, or complex recurrent disease makes a durable repair improbable. [1,2]
Isolated posterior leaflet prolapse is commonly repairable. Bileaflet prolapse, anterior leaflet prolapse, and Barlow-type disease are more complex but do not automatically require replacement. Repairability is determined by the complete valve phenotype, available tissue, annular geometry, and surgical expertise—not by prolapse severity alone.
2.2. Mitral stenosis and rheumatic disease
Severe symptomatic rheumatic mitral stenosis generally warrants intervention. Percutaneous balloon mitral commissurotomy is preferred in suitable anatomy without contraindications, particularly when leaflet mobility is preserved and calcification or subvalvular disease is limited. Surgery becomes necessary when the anatomy is unsuitable or catheter intervention is unsuccessful. Advanced commissural fusion, severe chordal fusion and shortening, and substantial leaflet calcification may necessitate replacement rather than open commissurotomy or repair. [1,2]
Rheumatic valves may exhibit mixed stenosis and regurgitation. The surgeon must assess the annulus, both leaflets, commissures, and chordal apparatus rather than basing the decision on the dominant Doppler lesion.
2.3. Secondary mitral regurgitation
Secondary regurgitation arises principally from ventricular or atrial remodeling rather than primary leaflet pathology. Guideline-directed heart failure treatment, resynchronization when indicated, and selected transcatheter therapies take priority in many patients. Surgery is considered within a broader ventricular and coronary strategy. In patients with severe ischemic mitral regurgitation who require an operation, chordal-sparing replacement may provide more reliable elimination of recurrent regurgitation than restrictive annuloplasty, although effects on survival and reverse remodeling are less clear. A randomized trial of 251 patients found substantially more recurrent moderate or severe regurgitation after repair at one year without a significant mortality difference. These findings should not be generalized to degenerative disease. [3]
2.4. Other circumstances
Replacement may be necessary for extensive infective endocarditis after adequate debridement when reconstructable tissue is insufficient; failed prior repair with unfavorable anatomy; severe mitral annular calcification (MAC); or congenital mitral dysplasia with irreparable stenosis or insufficiency. Active infection is not itself a reason to abandon repair when durable reconstruction remains achievable.
3. Functional and Operative Anatomy
3.1. Leaflets and commissures
The anterior leaflet is conventionally divided into A1, A2, and A3 and the posterior leaflet into P1, P2, and P3. The anterolateral commissure joins A1/P1 and the posteromedial commissure joins A3/P3. These labels describe correspondence rather than physically separate anterior leaflet scallops. The posterior leaflet has more distinct scallop indentations. Inspection must identify prolapse, tethering, calcification, perforation, and residual leaflet tissue at each segment.
The anterior annulus forms part of the aortomitral continuity near the right and left fibrous trigones. The posterior annulus is more prone to dilation and dystrophic calcification. The annulus is nonplanar and saddle-shaped; replacement imposes a prosthetic sewing-ring geometry onto a dynamic fibrous-muscular structure. Annular distortion, excessive suture tension, or inappropriate prosthetic orientation may affect seating and adjacent structures.
3.2. Chordae and papillary muscles
Primary (marginal), secondary, and basal chordae distribute leaflet tension to the anterolateral and posteromedial papillary muscles. The mitral apparatus is also a component of left ventricular systolic mechanics. Disruption of annular–papillary continuity can worsen postoperative ventricular function, particularly in a ventricle adapting to the abrupt elimination of chronic regurgitation. Historical comparative studies and small randomized data favor preserving suitable native chordal attachments during replacement when this can be accomplished safely. [4,5]
Posterior leaflet and chordal preservation is often technically straightforward, whereas anterior chordal preservation requires individualization to avoid left ventricular outflow tract obstruction, interference with mechanical leaflet excursion, or obstruction of prosthesis seating. Extensive calcification, infection, or heavily fused subvalvar structures may limit preservation.
3.3. Adjacent structures at risk
The circumflex coronary artery tracks in the atrioventricular groove close to portions of the posterior annulus, particularly in some left-dominant coronary patterns. Deep posterior annular sutures or aggressive calcium removal can injure the artery. The coronary sinus also courses posteriorly in the atrioventricular groove. Anteriorly, the aortomitral curtain and fibrous trigones demand careful tissue handling. The atrioventricular node and penetrating conduction axis are not immediately beneath the entire native mitral annulus, but associated septal surgery or congenital anatomic variation increases conduction risk.
4. Preoperative Evaluation and Planning
Transthoracic echocardiography establishes lesion severity, chamber remodeling, ventricular and right ventricular function, pulmonary pressure estimates, and concomitant valve disease. Transesophageal echocardiography, especially three-dimensional imaging, clarifies commissural pathology, leaflet restriction, mechanism of regurgitation, annular dimensions, and subvalvular architecture. Imaging should identify whether replacement is genuinely required and whether concomitant tricuspid, atrial arrhythmia, or coronary procedures are appropriate. [1,2]
For suspected severe MAC, gated cardiac CT can define the distribution and depth of calcium, extension into myocardium or fibrous trigones, and the anticipated feasibility of suture placement. CT is particularly useful when a heavily calcified annulus raises concerns about atrioventricular groove injury, prosthesis seating, or residual paravalvular leakage. Catheterization and coronary evaluation depend on age, cardiovascular risk, clinical findings, and the planned operation.
A practical preoperative assessment records valve mechanism, repair probability, annular size, chordal preservation strategy, ventricular reserve, and prosthesis-specific risks. For young patients, future somatic growth and access for subsequent replacement are major additional constraints.
5. Mechanical and Bioprosthetic Valve Selection
5.1. Mechanical prostheses
Modern bileaflet mechanical valves provide excellent structural durability but are thrombogenic and require lifelong vitamin K antagonist anticoagulation. For a contemporary mechanical prosthesis in the mitral position, the usual target is INR 3.0 (therapeutic range 2.5–3.5), individualized for valve type and patient-specific risk. Direct oral anticoagulants are contraindicated for mechanical valves. Warfarin monitoring, bleeding history, medication adherence, pregnancy planning, and access to anticoagulation services substantially influence suitability. [1,2]
The lower-pressure, lower-flow mitral inflow environment carries substantial prosthetic thrombosis concerns. Mechanical leaflet opening and closure must be unobstructed by retained tissue, chordae, sutures, or prosthetic struts. Preserving annular-papillary continuity is desirable only when it does not compromise prosthesis function.
5.2. Bioprosthetic valves
Surgical bioprostheses avoid the need for lifelong prosthesis-related warfarin in patients without another anticoagulation indication; however, short-term postoperative anticoagulation may be appropriate, and atrial fibrillation or other conditions can require continuing treatment. Tissue valves undergo structural valve deterioration that may produce progressive stenosis or regurgitation and necessitate reintervention. The pace of deterioration varies with patient age, valve design, calcification biology, and clinical context. [1,2]
Bioprostheses may be advantageous when anticoagulation is contraindicated, difficult to maintain, or inconsistent with patient preference. Future transcatheter mitral valve-in-valve intervention is sometimes possible but cannot be assumed; the original internal prosthetic diameter, anticipated residual gradient, and risk of left ventricular outflow tract obstruction matter at the first operation.
5.3. Choosing between them
Valve selection is a shared lifetime-management decision, not a rigid age cutoff. Guidelines incorporate patient age, life expectancy, reoperation risk, bleeding/thromboembolic risk, pregnancy considerations, and informed preference. Observational studies comparing prosthesis types suggest a tradeoff: mechanical prostheses generally reduce repeat replacement, whereas bioprostheses avoid lifelong prosthesis-related anticoagulation and may reduce anticoagulation-associated bleeding. Survival comparisons are susceptible to selection bias and differ by age and cohort. [6,7]
In children, small annular diameter, growth, anticoagulation challenges, and early prosthesis–patient mismatch complicate either choice. Replacement should generally follow careful assessment of every reasonable reconstructive option. Pediatric outcome data are predominantly retrospective and must be interpreted according to anatomy, age, and prosthetic position. [8]
6. Essential Operative Considerations
Although specific implantation techniques vary, several principles govern safe MVR:
- Exposure and assessment. After cardiopulmonary bypass and cardioplegic arrest, the left atrium is opened through an approach suited to atrial size, prior operations, and associated procedures. The surgeon directly confirms the leaflet, commissural, annular, and chordal findings and reassesses repair feasibility.
- Resection with preservation. Diseased or obstructive leaflet components are removed selectively while preserving competent chordal attachments whenever safe. Retained tissue should not restrict the prosthetic orifice or project into the left ventricular outflow tract.
- Annular preparation. The annulus is inspected for calcium, friability, infection, and adequate suture-bearing tissue. In severe MAC, extensive en bloc decalcification may produce atrioventricular groove disruption, circumflex injury, or hemorrhage. Alternatives include selected calcium-preserving, reconstructive, or supra-annular strategies; each has distinct tradeoffs. [9]
- Sizing and orientation. Sizing should be atraumatic. An oversized prosthesis risks annular injury, malposition, outflow obstruction, and interference with adjacent anatomy; undersizing can cause excessive inflow gradients. For mechanical valves, orientation must permit full leaflet excursion without interference.
- Seating and verification. Sutures must capture stable tissue circumferentially without distortion. Before atrial closure, verify a secure sewing-ring interface and free prosthetic mobility. Transesophageal echocardiography after separation from bypass assesses leaflet motion, transmitral gradients at the prevailing flow and heart rate, paravalvular leakage, ventricular function, and outflow obstruction.
The illustrated mechanical valve emphasizes the circumferential sewing ring and bileaflet occluder, but not every prosthesis or suture technique has identical geometry.
7. Postoperative Physiology and Surveillance
Following correction of chronic mitral regurgitation, the left ventricle no longer ejects into a low-impedance left atrial circuit. An apparent early decline in ejection fraction may therefore reflect altered loading conditions and reveal preexisting myocardial dysfunction rather than technical failure alone. Adequate forward output, ventricular filling, rhythm, right ventricular performance, pulmonary vascular resistance, and prosthetic function all require surveillance.
Postoperative echocardiography establishes a baseline for prosthetic gradients and regurgitation. A high transmitral gradient must be interpreted alongside prosthesis model and labeled size, flow state, heart rate, anemia, and potential obstruction rather than assigned automatically to prosthesis–patient mismatch. Suspected mechanical thrombosis, restricted occluder motion, new embolic events, or hemolysis warrants prompt multimodality evaluation. Chronic follow-up incorporates symptoms, examination, anticoagulation management, and imaging according to prosthesis type and clinical change. [1,2]
Major replacement-related complications include hemorrhage, valve thrombosis, systemic embolism, infective endocarditis, paravalvular leak, hemolysis, structural bioprosthetic degeneration, prosthesis–patient mismatch, and reoperation. Severe MAC increases the complexity and potential severity of annular complications.
8. Key Clinical and Surgical Principles
- Durability determines the threshold for replacement: severe prolapse alone does not establish that repair is impossible.
- Define the entire apparatus: leaflet segments, commissures, annulus, chordae, and papillary muscles together determine operative strategy.
- Preserve ventricular geometry when safe: retain useful annular–papillary continuity without compromising prosthetic motion or outflow.
- Treat annular calcium as a structural hazard: plan suture-bearing zones and avoid unnecessary deep decalcification.
- Select the prosthesis for the patient's lifetime: mechanical durability must be balanced against anticoagulation, while tissue-valve freedom from lifelong prosthesis-related warfarin must be balanced against degeneration and reintervention.
- Verify functional implantation: assess occluder excursion, paravalvular leakage, gradients, left ventricular function, and left ventricular outflow tract patency before completion.
References
- Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46:4635–4736. DOI: 10.1093/eurheartj/ehaf194. PMID: 40878295.
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77:e25–e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.
- Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014. DOI: 10.1056/NEJMoa1312808.
- David TE, Burns RJ, Bacchus CM, Druck MN, Weisel RD. Mitral valve replacement for mitral regurgitation with and without preservation of chordae tendineae. J Thorac Cardiovasc Surg. 1984. DOI: 10.1016/S0022-5223(19)35439-X. PMID: 6492840.
- Okita Y, Miki S, Ueda Y, Tahata T, Sakai T. Left ventricular function after mitral valve replacement with or without chordal preservation. J Heart Valve Dis. 1995. PMID: 8563996.
- Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med. 2017. DOI: 10.1056/NEJMoa1613792. PMID: 29117490.
- Chikwe J, Chiang YP, Egorova NN, et al. Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years. JAMA. 2015. DOI: 10.1001/jama.2015.3164. PMID: 25871669.
- Beierlein W, Becker V, Yates R, et al. Long-term follow-up after mitral valve replacement in childhood: poor event-free survival in the young child. Eur J Cardiothorac Surg. 2007. DOI: 10.1016/j.ejcts.2007.02.006. PMID: 17383889.
- Hashmi Z, Rajeev R, Kwon YIC. The atrial neoannulus technique for mitral valve replacement in patients with severe mitral annular calcification. JTCVS Techniques. 2025. DOI: 10.1016/j.xjtc.2025.05.001. PMID: 40814665.